TRACeR Systems for General Targeting of MHC-Antigens
Event details
| Date | 18.03.2025 |
| Hour | 14:15 › 15:15 |
| Speaker | Prof. Possu Huang, Stanford University, California (USA) |
| Location | Online |
| Category | Conferences - Seminars |
| Event Language | English |
BIOENGINEERING SEMINAR
Abstract:
MHC antigens are critical in mediating immune responses. We recently reported two general platforms for facile creation of targeting proteins for MHC-I and MHC-II, called TRACeR-I and TRACeR-II, respectively. They use unconventional binding modes and enable highly specific peptide recognition through a handful of residues. In vitro testing has shown effective tumor cell killing, as well as potential inflammation controls. In this seminar, I will introduce these platforms and the engineering principles behind them.
Bio:
Dr. Possu Huang received his PhD from Caltech with the first demonstration of a computationally designed novel protein-protein interface. He subsequently conducted postdoctoral research at the University of Washington before starting his group at Stanford. His research focuses on advancing the understanding of proteins for the engineering of novel therapeutics and other protein-based nanotechnology. He has contributed to a large number of de novo designed proteins, most notably to the unlocking of the design principles behind the TIM barrel fold and the invention of eOD, an HIV immunogen design. His group uses machine learning, computational modeling, structural biology and experimental library optimization to continue the expansion of protein-based molecular platforms.
Education:
Senior Fellow, University of Washington
Ph.D., California Institute of Technology, Biochemistry and Molecular Biophysics
B.A., UC Berkeley, MCB - Biochemistry
Zoom link for attending remotely: https://epfl.zoom.us/j/64280931807
Abstract:
MHC antigens are critical in mediating immune responses. We recently reported two general platforms for facile creation of targeting proteins for MHC-I and MHC-II, called TRACeR-I and TRACeR-II, respectively. They use unconventional binding modes and enable highly specific peptide recognition through a handful of residues. In vitro testing has shown effective tumor cell killing, as well as potential inflammation controls. In this seminar, I will introduce these platforms and the engineering principles behind them.
Bio:
Dr. Possu Huang received his PhD from Caltech with the first demonstration of a computationally designed novel protein-protein interface. He subsequently conducted postdoctoral research at the University of Washington before starting his group at Stanford. His research focuses on advancing the understanding of proteins for the engineering of novel therapeutics and other protein-based nanotechnology. He has contributed to a large number of de novo designed proteins, most notably to the unlocking of the design principles behind the TIM barrel fold and the invention of eOD, an HIV immunogen design. His group uses machine learning, computational modeling, structural biology and experimental library optimization to continue the expansion of protein-based molecular platforms.
Education:
Senior Fellow, University of Washington
Ph.D., California Institute of Technology, Biochemistry and Molecular Biophysics
B.A., UC Berkeley, MCB - Biochemistry
Zoom link for attending remotely: https://epfl.zoom.us/j/64280931807
Practical information
- Informed public
- Free
Organizer
- Prof. Bruno Correia, Institute of Bioengineering
Contact
- Institute of Bioengineering (IBI), Dietrich REINHARD